If you have been on two or more antidepressants and still feel depressed, you may have been told you have treatment-resistant depression. The label is technically useful but often poorly explained. It does not mean your depression cannot be treated. It does not mean you have done something wrong. It means the medications most commonly tried first have not worked for you, and the next steps require a different approach.
This article walks through what treatment-resistant depression actually is, the most common reasons people end up there, and the medication and non-medication options that work when standard antidepressants have not. Several of those options have only become available in the past few years and represent the most significant change in depression treatment in decades.
What treatment-resistant depression actually means
Treatment-resistant depression (TRD) is most commonly defined as failure to achieve adequate response to two or more antidepressant trials, each given at an adequate dose for an adequate duration. The specific definitions vary across guidelines, but the core elements are consistent: two failed trials, adequate dosing, and adequate time.
The two qualifiers matter more than they sound. “Adequate dose” means a dose at or near the maximum recommended for that medication, sustained long enough to produce its effect, not a starting dose that was never titrated. “Adequate duration” means at least six to eight weeks at that adequate dose. Many people labeled as treatment-resistant have actually had inadequate trials: medications stopped because of early side effects, doses never increased to a therapeutic range, or treatment terminated after four weeks because the response was incomplete (which is often how antidepressants look at four weeks before the full effect develops).
Before accepting a TRD label, the right question is whether your previous antidepressant trials were actually adequate. If you stopped a medication at week three because of nausea, that is not a failed trial. If you tried sertraline at 50 mg for two months without titrating up, you may not have reached a therapeutic dose. A careful review of past trials often changes the picture.
There is also a distinction between partial response and non-response. Partial response means the medication helped some, but not enough. Non-response means no meaningful change. Each suggests different next steps: partial response often points toward augmentation (adding a second medication to the first), while non-response often points toward switching to a different medication class.
How common is treatment-resistant depression?
Treatment-resistant depression is not rare. Estimates from major academic medical centers including Johns Hopkins and Columbia put the prevalence at approximately 30 percent of people with major depressive disorder. The STAR*D study, the largest sequential trial of antidepressant treatments to date, followed over 4,000 patients through up to four sequential medication trials and found that cumulative remission rates declined with each successive trial. About one-third of patients achieved remission on the first medication; another portion responded to switching or augmentation; a significant minority remained symptomatic after all four levels of treatment.
This is a common situation, not an unusual one. The reason it can feel isolating is that conversations about depression treatment often assume the first medication will work, and people whose treatment goes differently sometimes blame themselves rather than recognizing how often the standard path needs adjustment.
Why standard treatment doesn’t always work: common causes
Standard antidepressants fail for several reasons, and identifying which one applies to a given person changes what should happen next.
Misdiagnosis is the most important and most missed cause. Several conditions look like depression at first glance but require different treatment. Bipolar disorder, particularly bipolar II, is the most common misdiagnosis. People with bipolar II depression often look identical to people with major depressive disorder until you ask carefully about past episodes of unusual energy, decreased need for sleep, racing thoughts, or impulsive behavior. Standard antidepressants alone for bipolar depression often produce poor results or trigger manic switches. For more on this distinction, see Best Medication for Bipolar Depression and Medication for Bipolar Disorder.
ADHD with depression is another commonly missed pattern. The chronic underperformance, executive dysfunction, and emotional dysregulation of untreated ADHD can produce a depressive picture that does not respond well to antidepressants alone. Anxiety disorders, particularly generalized anxiety and post-traumatic stress disorder, can also present primarily as low mood and respond differently from straightforward depression.
Inadequate treatment trials are the second major cause, as mentioned above. Doses never increased to therapeutic levels, treatments stopped at four weeks before the full effect developed, or medications discontinued because of manageable side effects all fall into this category.
Co-occurring medical conditions can drive treatment resistance directly. Hypothyroidism is the most common: an underactive thyroid produces fatigue, low mood, weight gain, and cognitive slowing that mimics depression and does not respond to antidepressants unless the thyroid issue is treated. Vitamin B12 deficiency, vitamin D deficiency, sleep apnea, chronic pain, and chronic inflammation all have similar effects. A basic medical workup including thyroid panel, B12, vitamin D, and a sleep evaluation is part of any thorough treatment-resistant depression evaluation.
Substance use affects both the depression itself and the response to medication. Alcohol, in particular, is depressogenic at any level above modest use and reduces the effectiveness of most antidepressants. Cannabis use, especially daily use, has been associated with reduced antidepressant response in several studies. Stimulant use (cocaine, methamphetamine) and opioid use have stronger effects on mood and treatment response.
Genetic factors affecting medication metabolism explain some cases. The CYP450 enzyme system in the liver metabolizes most antidepressants, and genetic variations affect how quickly an individual processes specific medications. Pharmacogenomic testing (commercial panels like GeneSight) can identify rapid metabolizers (who clear medications too quickly for them to work at standard doses) and poor metabolizers (who experience side effects at low doses). The clinical value of these tests is debated, but for someone who has had unusual responses to multiple antidepressants, the information can be useful.
Psychological and situational factors sometimes contribute. Chronic interpersonal stress, ongoing trauma, unprocessed grief, or significant life circumstances may produce depressive symptoms that medication alone cannot fully address. This does not mean medication is the wrong answer, but it does mean medication plus therapy often produces better results than medication alone.
Reassessing the diagnosis: the first step before declaring TRD
Before pursuing more aggressive treatment, a careful reassessment is often the highest-value step. This is the part most overview articles skip.
A thorough reassessment for treatment-resistant depression includes several elements. A detailed history of every depressive episode and any periods of unusual energy, decreased sleep, or impulsive behavior, to evaluate for bipolar disorder. An ADHD screen, particularly for adults whose attention and executive function problems predate their depression. A trauma history and PTSD screen. A substance use history with specific attention to alcohol and cannabis. A basic medical workup including thyroid function, B12, vitamin D, and screening for sleep disorders. A review of every antidepressant trial: dose reached, duration sustained, reason for discontinuation, partial versus full response.
This is what a careful psychiatric evaluation looks like for someone whose depression has not responded to standard treatment. It is more involved than a 20-minute medication adjustment visit. At Gimel Health, my initial consultation for someone in this situation is 50 minutes specifically because the reassessment matters more than picking the next medication quickly.
Medication strategies for treatment-resistant depression
If reassessment confirms major depressive disorder and the previous trials were adequate, the medication options expand significantly.
Switching classes is often the first step. If two SSRIs have failed, switching to an SNRI (venlafaxine, duloxetine) or to bupropion is a reasonable next move. Bupropion in particular has a different mechanism (dopamine and norepinephrine, not serotonin) and sometimes works for people who have not responded to serotonergic antidepressants.
Augmentation strategies add a second medication to the existing antidepressant rather than replacing it. Several augmentation approaches have FDA approval or strong evidence.
Atypical antipsychotics are the most common augmentation category. Aripiprazole, brexpiprazole, cariprazine, and quetiapine all hold FDA approval as adjunctive treatment for major depressive disorder. They are added to an existing antidepressant rather than used alone, and they typically produce additional symptom reduction within two to four weeks. Side effects vary by medication; metabolic effects (weight gain, blood sugar, cholesterol) are the main concern for long-term use.
Lithium augmentation has decades of evidence for treatment-resistant depression and is particularly useful for patients with frequent recurrence or any history of bipolar features. Lithium adds the benefit of suicide-risk reduction that is unique among psychiatric medications.
T3 (triiodothyronine) augmentation is less well known but has reasonable evidence. Adding a small dose of T3 to an existing antidepressant can produce additional response in some patients, particularly those with subclinical thyroid dysfunction.
Bupropion plus SSRI combinations are commonly used and can address both the depression and the sexual side effects that often come with SSRIs.
Newer oral options include Auvelity (a combination of dextromethorphan and bupropion, FDA-approved in 2022 for major depressive disorder). It works on the NMDA glutamate system, similar to ketamine, and offers a faster onset than traditional antidepressants.
Brain stimulation therapies: TMS, ECT, and newer options
Non-medication interventions have a significant and underused role in treatment-resistant depression.
Transcranial magnetic stimulation (TMS) is a non-invasive treatment that uses magnetic pulses to stimulate specific brain regions involved in mood regulation. TMS is FDA-approved for treatment-resistant depression and has been in clinical use since 2008. The standard protocol involves daily 30-minute sessions over four to six weeks. Side effects are generally mild: scalp discomfort at the stimulation site and occasional headaches. TMS does not require anesthesia, sedation, or recovery time. Newer accelerated protocols (including the SAINT protocol developed at Stanford) compress the treatment course into days rather than weeks, with high reported remission rates in initial studies.
Electroconvulsive therapy (ECT) remains the most effective treatment for severe treatment-resistant depression, particularly when suicidal thoughts or psychotic features are present. Modern ECT bears little resemblance to its historical reputation. It is performed under brief general anesthesia in a controlled setting, uses precise electrical dosing, and produces minimal physical discomfort. Memory effects are the main concern: short-term memory disruption around the treatment period is common and usually resolves within weeks of completing the course. ECT is used less often than its evidence base would justify, largely because of historical stigma. For someone with severe, persistent depression who has not responded to medications, ECT deserves a serious conversation.
Vagus nerve stimulation (VNS) is FDA-approved for chronic, severe treatment-resistant depression. It involves a small implanted device that stimulates the vagus nerve. VNS is used less commonly than TMS or ECT, partly because it requires a minor surgical procedure and partly because the onset of effect is gradual.
Deep brain stimulation (DBS) is the most invasive option and is reserved for the most severe, treatment-resistant cases. It involves implantation of electrodes in specific brain regions and is still considered experimental for depression at most centers. Research is ongoing.
Gimel Health offers integrated treatment for resistant depression that incorporates evidence-based medication strategies and coordination with brain stimulation therapies where appropriate.
Ketamine, esketamine, and the new pharmacology of depression
The most significant change in depression treatment in the past 30 years has been the recognition that the glutamate system, beyond serotonin and norepinephrine alone, can be targeted to produce rapid antidepressant effects.
Esketamine (Spravato) is an FDA-approved nasal spray for treatment-resistant depression, available since 2019. It is administered in a healthcare setting under monitoring because of the potential for dissociation and elevated blood pressure during the treatment session. Esketamine works on the NMDA glutamate receptor, a completely different mechanism from SSRIs and SNRIs. The clinical impact: where standard antidepressants take four to eight weeks to produce their effect, esketamine can produce noticeable improvement within hours to days. For people who have been depressed for months or years on standard medications, this represents a genuinely different option.
Racemic ketamine (IV ketamine) is the original form of the molecule from which esketamine was developed. It is used off-label for treatment-resistant depression at specialized clinics and is often more accessible and less expensive than esketamine, though insurance coverage is more variable. The clinical effects are similar.
Zuranolone (Zurzuvae) is a newer oral medication FDA-approved for postpartum depression. It works on the GABA-A receptor system and produces rapid antidepressant effects over a two-week course. Investigation is ongoing for broader applications in treatment-resistant depression.
Psychedelic-assisted therapy with psilocybin is in late-stage clinical trials for treatment-resistant depression and has received FDA breakthrough therapy designation. It is not yet FDA-approved or commercially available at the time of writing. The early research suggests significant and durable effects from a small number of treatment sessions combined with structured psychotherapy. Whether and when these treatments become available will depend on the outcomes of phase 3 trials and the FDA approval process.
These newer options are not right for everyone. Access varies significantly by location, insurance status, and the specific clinic’s protocols. Costs can be substantial for those without insurance coverage. But for someone whose depression has not responded to multiple standard treatments, the options available now are meaningfully better than what existed even a decade ago.
When to consider TRD-specific treatment
The right time to consider treatment-resistant depression options is after two adequate antidepressant trials have failed to produce meaningful improvement, particularly if symptoms are severe, persistent, or significantly affecting your daily life. Other reasons to escalate include any history of suicidal thoughts during the current episode, diminishing response to a medication that previously worked, and the development of new symptoms suggesting a different or co-occurring diagnosis.
When you bring this conversation to a clinician, the most useful information you can prepare includes a complete list of every antidepressant you have tried, the dose you reached on each, how long you stayed on each, why you stopped (side effects, lack of response, partial response that was not enough), and any episodes of unusual energy or impulsivity that may not have been explored before. A careful review of this history is the foundation of an informed next step. For more on what to expect from medication management generally, see Medication Management in NJ: What to Expect From a Psychiatrist.
When to take the next step
Treatment-resistant depression is one of the most common but least well-served situations in psychiatric care. People who have been through several antidepressants without adequate improvement often blame themselves or assume nothing will work. Neither is accurate. The treatment options available now (newer medications, augmentation strategies, brain stimulation therapies, glutamate-targeting agents) work for many people whose previous treatment failed.
I provide precision psychiatry and medication management for patients in New Jersey (in-person at Fort Lee) and New York (telehealth), with specialized focus on treatment-resistant depression. Initial consultations are 50 minutes and include a careful review of your previous treatment history, screening for the conditions that often produce treatment resistance, and a plan for the next step based on what your specific picture shows.
For trusted general reference on treatment-resistant depression, the National Institute of Mental Health maintains current information on standard and emerging treatments.
